Methods of treating inflammatory and autoimmune diseases with natalizumab
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
1. A method of using natalizumab to treat a patient with an inflammatory or autoimmune disease comprising:
(a) administering a pharmaceutically effective amount of natalizumab to the patient;
(b) monitoring the patient for indicators of progressive multifocal leukoencephalopathy (PML), wherein the monitoring comprises detecting seroconversion and/or an increasing titer of JC virus (JCV) antibodies in the patient's blood; and
(c) discontinuing the administration of natalizumab in the presence of seroconversion and/or an increasing titer of JCV antibodies;
wherein the monitoring improves the safety of the treatment.
2. The method of claim 1 , wherein the disease is multiple sclerosis.
3. The method of claim 2 , wherein the multiple sclerosis is selected from relapsing remitting, secondary progressive, primary progressive, and chronic progressive multiple sclerosis.
4. The method of claim 3 , wherein the disease is relapsing remitting multiple sclerosis.
5. The method of claim 1 , wherein the disease is inflammatory bowel disease.
6. The method of claim 5 , wherein the disease is Crohn's disease.
7. The method of claim 1 , wherein the monitoring further comprises testing for clinical and/or radiologic symptoms of progressive multifocal leukoencephalopathy (PML).
8. The method of claim 7 , wherein the testing for clinical symptoms comprises testing for new or worsening neurological symptoms.
9. The method of claim 8 , wherein the neurological symptoms comprise one or more of central blindness, mental confusion, personality change, and dyskinesia.
10. The method of claim 7 , wherein the testing for radiologic symptoms comprises performing a Gd-enhanced magnetic resonance imaging (MRI) scan.
11. The method of claim 1 , wherein the pharmaceutically effective amount is from 1 to 5 mg antibody per kilogram of body weight.
12. The method of claim 1 , wherein the pharmaceutically effective amount is 300 mg.
13. The method of claim 1 , wherein the natalizumab is administered repeatedly at intervals from two to eight weeks.
14. The method of claim 1 , wherein the monitoring the patient for indicators of PML further comprises detecting the presence of JCV in the patient's cerebrospinal fluid (CSF).
15. The method of claim 1 , wherein detecting seroconversion and/or an increasing titer of JCV antibodies in the patient's blood comprises serially removing samples of the patient's blood, measuring the amount of IgG anti-JCV antibodies in the samples, and comparing the amount of the anti-JCV antibodies in the samples.
16. The method of claim 1 , wherein in the presence of seroconversion and/or an increasing titer of JCV antibodies the method further comprises providing said patient with at least one treatment selected from intravenous immunoglobulin therapy, plasmapheresis, and antiviral therapy.